Role of sorafenib in renal cell carcinoma: focus on elderly patients.

Research output: Contribution to journalArticle

Abstract

Mounting evidence suggests that, in order to optimize therapeutic benefits, it is important to consider the range of parameters and characteristics relevant to each individual patient. Of note, the six targeted therapies currently approved for the treatment of advanced/metastatic renal cell carcinoma have not been evaluated in all relevant settings and in all prognostic groups. Among different agents currently licensed for the treatment of renal cell carcinoma, sorafenib was the first therapy to show improvements in progression-free survival and overal survival in Phase III trials. This article will discuss the current role of sorafenib in the treatment of elderly patients with renal cell carcinoma.

Original languageEnglish
Pages (from-to)1689-1692
Number of pages4
JournalExpert Review of Anticancer Therapy
Volume11
Issue number11
Publication statusPublished - Nov 2011

Fingerprint

Renal Cell Carcinoma
Therapeutics
Disease-Free Survival
sorafenib
Survival

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Role of sorafenib in renal cell carcinoma : focus on elderly patients. / Procopio, Giuseppe.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 11, 11.2011, p. 1689-1692.

Research output: Contribution to journalArticle

@article{0e5675c501bc4d47ac64188475f338ba,
title = "Role of sorafenib in renal cell carcinoma: focus on elderly patients.",
abstract = "Mounting evidence suggests that, in order to optimize therapeutic benefits, it is important to consider the range of parameters and characteristics relevant to each individual patient. Of note, the six targeted therapies currently approved for the treatment of advanced/metastatic renal cell carcinoma have not been evaluated in all relevant settings and in all prognostic groups. Among different agents currently licensed for the treatment of renal cell carcinoma, sorafenib was the first therapy to show improvements in progression-free survival and overal survival in Phase III trials. This article will discuss the current role of sorafenib in the treatment of elderly patients with renal cell carcinoma.",
author = "Giuseppe Procopio",
year = "2011",
month = "11",
language = "English",
volume = "11",
pages = "1689--1692",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Role of sorafenib in renal cell carcinoma

T2 - focus on elderly patients.

AU - Procopio, Giuseppe

PY - 2011/11

Y1 - 2011/11

N2 - Mounting evidence suggests that, in order to optimize therapeutic benefits, it is important to consider the range of parameters and characteristics relevant to each individual patient. Of note, the six targeted therapies currently approved for the treatment of advanced/metastatic renal cell carcinoma have not been evaluated in all relevant settings and in all prognostic groups. Among different agents currently licensed for the treatment of renal cell carcinoma, sorafenib was the first therapy to show improvements in progression-free survival and overal survival in Phase III trials. This article will discuss the current role of sorafenib in the treatment of elderly patients with renal cell carcinoma.

AB - Mounting evidence suggests that, in order to optimize therapeutic benefits, it is important to consider the range of parameters and characteristics relevant to each individual patient. Of note, the six targeted therapies currently approved for the treatment of advanced/metastatic renal cell carcinoma have not been evaluated in all relevant settings and in all prognostic groups. Among different agents currently licensed for the treatment of renal cell carcinoma, sorafenib was the first therapy to show improvements in progression-free survival and overal survival in Phase III trials. This article will discuss the current role of sorafenib in the treatment of elderly patients with renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84858717040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858717040&partnerID=8YFLogxK

M3 - Article

C2 - 22050017

AN - SCOPUS:84858717040

VL - 11

SP - 1689

EP - 1692

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 11

ER -